Cronos Group Inc. (CRON)
NASDAQ: CRON · Real-Time Price · USD
2.780
+0.100 (3.73%)
At close: Jan 23, 2026, 4:00 PM EST
2.820
+0.040 (1.44%)
After-hours: Jan 23, 2026, 7:59 PM EST
Cronos Group Revenue
Cronos Group had revenue of $36.34M in the quarter ending September 30, 2025, with 6.06% growth. This brings the company's revenue in the last twelve months to $132.36M, up 19.00% year-over-year. In the year 2024, Cronos Group had annual revenue of $117.62M with 34.82% growth.
Revenue (ttm)
$132.36M
Revenue Growth
+19.00%
P/S Ratio
8.05
Revenue / Employee
$288,359
Employees
459
Market Cap
1.07B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 117.62M | 30.37M | 34.82% |
| Dec 31, 2023 | 87.24M | 492.00K | 0.57% |
| Dec 31, 2022 | 86.75M | 22.19M | 34.37% |
| Dec 31, 2021 | 64.56M | 17.84M | 38.19% |
| Dec 31, 2020 | 46.72M | 22.97M | 96.71% |
| Dec 31, 2019 | 23.75M | 11.63M | 95.94% |
| Dec 31, 2018 | 12.12M | 8.97M | 285.16% |
| Dec 31, 2017 | 3.15M | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | -572.29K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Phibro Animal Health | 1.40B |
| Evotec SE | 887.40M |
| Tilray Brands | 837.32M |
| Collegium Pharmaceutical | 757.07M |
| Amphastar Pharmaceuticals | 723.31M |
| Pacira BioSciences | 716.79M |
| BioCryst Pharmaceuticals | 599.82M |
| Ironwood Pharmaceuticals | 338.99M |
CRON News
- 9 days ago - 3 Marijuana Stocks For Investors To Make Money In 2026 - MarijuanaStocks
- 15 days ago - Marijuana industry taking fight against Wall Street blockades straight to Trump - New York Post
- 18 days ago - Best Canadian Cannabis Stocks to Watch Entering 2026 - MarijuanaStocks
- 25 days ago - Cronos: A Standout Balance Sheet Among Its Peers - Seeking Alpha
- 25 days ago - Trump Is Warming to Cannabis, but Investors Aren't Impressed - WSJ
- 4 weeks ago - Marijuana Stocks To Watch After The Holidays - MarijuanaStocks
- 5 weeks ago - Inside the dealmaking that pushed Trump to reclassify pot, expand access - CNBC
- 5 weeks ago - After Trump's move to reclassify cannabis, here's what Wall Street is thinking - Market Watch